Stock News
KalVista To Pioneer Plasma Kallikrein Inhibitor Therapy For Diabetic Macular Edema – Kalvista Pharmaceuticals (NASDAQ:KALV)
Preface The following article was originally published for subscribers of my exclusive marketplace, The Formula, last month when KALV was trading at $17.05/share. Timeline Price Target Relevant Events 12-18 months $30 Positive KVD001 data Asset […]